A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Clinical Cancer Research|2018Cited by 236
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Kathleen Kelly, Aida Mariani et al.|Journal of Clinical Investigation|2023Cited by 33
Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerSupreet Agarwal, Kathleen Kelly, Lei Fang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1
Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Unknown|2023Cited by 0
Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Unknown|2023Cited by 0